High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia
High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia
复制标题
DOI：
10.1038/sj.bjc.6602771
复制
发表时间：
2005-09-19
影响因子：
8.8
通讯作者：
Hancock, BW
中科院分区：
文献类型：
--
作者：
El-Helw, LM;Seckl, MJ;Hancock, BW
我们回顾性地介绍了迄今为止报道的最大系列中使用大剂量化疗和造血干细胞支持（HSCS）治疗难治性妊娠滋养细胞肿瘤（GTN）的经验。1993年至2004年间，共有11名患者在三个滋养层中心接受了治疗。预处理方案包括Carbop-EC-T（卡铂、依托泊苷、环磷酰胺、紫杉醇和泼尼松龙）或CEM（卡铂、依托泊苷和美法仑）或ICE（异环磷酰胺、卡铂、依托泊苷）。2例患者完全人绒毛膜促性腺激素反应，1例持续4个月，另1例持续12个月。3例患者的肿瘤标志物部分缓解持续1 - 2个月。大剂量化疗和HSCS治疗GTN仍未经证实。需要进一步的研究，也许是在第一次挽救治疗失败的高危患者中。
We present retrospectively our experience in the use of high-dose chemotherapy and haematopoietic stem cell support (HSCS) for refractory gestational trophoblastic neoplasia (GTN) in the largest series so far reported. In all, 11 patients have been treated at three Trophoblast Centres between 1993 and 2004. The conditioning regimens comprised either Carbop-EC-T ( carboplatin, etoposide, cyclophosphamide, paclitaxel and prednisolone) or CEM ( carboplatin, etoposide and melphalan) or ICE ( ifosfamide, carboplatin, etoposide). Two patients had complete human chorionic gonadotrophin responses, one for 4 and the other for 12 months. Three patients had partial tumour marker responses for 1 - 2 months. High-dose chemotherapy and HSCS for GTN is still unproven. Further studies are needed, perhaps in high-risk patients who fail their first salvage treatment.